Top oncology conference 2025, nursing conference, cancer biology conference, therapeutics conference, top oncology conference, global oncology conference, top nursing conference, global nursing conference, top cancer biology conference, global cancer biology conference, top therapeutics conference, global therapeutics conference.

Renowned Speakers

Nandini N.M

JSS Academy Of Higher Education And Research, India

Daphne Gschwantler-Kaulich

Medical University of Vienna, Austria

Antoni Ribas

University of California Los Angeles (UCLA), USA

Carlos Caldas

University of Cambridge, UK

Fabrice Andre

Gustave Roussy, France

Omar Khan

Oncologist at Shalbourne Private Healthcare, UK

Jennie R Lill

Cancer Biology Researcher USA

Dana Haddad

Head of Breast Imaging HealthBay Polyclinic, UAE

Recommended Global Oncology & Cancer Webinars & Conferences

Europe & UK

Euro Cancer 2025, Spain Cancer Meeting Summit 2025, France Cancer Research 2025, Spain Breast Cancer-2025, Germany Women Oncology-2025, UK

Asia Pacific & Middle East

Canada

Breast Cancer 2025, Canada

CANCER BIOLOGY- 2025

About Conference

Discounts are available until this weekend, December 21, 2024.

Welcome to the 3^rd international conference on Cancer Biology and Therapeutics, scheduled for June 09-10, 2025, in Rome, Italy. we're excited to bring together specialists and fans in the subject for an enriching revel in, packed with insightful discussions and networking opportunities. be a part of us in the beautiful metropolis of Rome, Italy, for this wonderful event focused on advancing expertise and practices in cancer Biology and cancer Therapeutics.

CANCER BIOLOGY-2025 will function a dynamic platform for researchers, clinicians, healthcare professionals, scientists, and students to present their research and new strategies inside the fields of most cancers Biology, Oncology, Breast most cancers, and numerous different associated subjects. The conference goals to foster collaboration and address key problems in each industry and academia.

Attendees can anticipate keynote lectures from senior scientists and enterprise experts, panel discussions, poster competitions, and a younger Researcher forum. The occasion will spotlight interactive sessions and sub-sessions that emphasize innovation and emerging trends in most cancers Biology.

young Researcher Awards at most CANCER BIOLOGY-2025 will recognize remarkable master's, PhD, and post-Doctorate thesis work via the younger Researcher forum. restricted to just 25 presentations, this discussion board is a part of the bigger Cancer Biology-2025 convention, which serves as a top of the line occasion for researchers from round the sector to percentage their understanding and collaborate on progressive solutions within the combat against cancer.

Mark your calendar and keep track of CANCER BIOLOGY- 2025 deadlines:

Abstract Submission Deadline: 24 December 2024 (*)
1st Phase Registration Deadline: 20 December 2024 (*)
Notification of Abstract Acceptance/Rejection: 2-3 days (*)
World Cancer 2025 Dates: June 09-10, 2025 | Rome, Italy

Sessions and Tracks

Track 01: Cancer Biology

Cancer Biology focuses on understanding the mechanisms that drive cancer development, progression, and metastasis. It delves into the genetic, cellular, and molecular aspects of cancer, including the role of oncogenes, tumor suppressor genes, and cell cycle dysregulation. The track also explores immune evasion strategies and the interactions between tumor cells and the surrounding microenvironment that contribute to cancer's aggressive nature. By investigating the fundamental processes of cancer biology, this track aims to uncover novel targets for therapeutic intervention and improve the molecular understanding of cancer.

Track 02: Molecular Biology of Cancer

Molecular Biology of Cancer explores the genetic and epigenetic alterations that drive cancer initiation and progression. This track covers gene mutations, chromosomal abnormalities, and the molecular pathways that regulate cancer development. It also examines the role of microRNAs, DNA repair mechanisms, and epigenetic modifications in tumor malignancy and resistance to therapies. By understanding these molecular mechanisms, the track aims to uncover new insights for improving cancer diagnosis, identifying novel biomarkers, and developing more effective treatment strategies.

Track 03: Cancer Genomics and Epigenetics

Cancer Genomics and Epigenetics investigates the genetic and epigenetic alterations that drive tumorigenesis. This track explores the role of DNA methylation, histone modifications, and non-coding RNAs in cancer development. It also covers advanced technologies like next-generation sequencing and CRISPR, providing insights into how genomic and epigenetic changes influence cancer biology. By understanding these alterations, the track aims to advance cancer research and contribute to the development of more precise diagnostic tools and targeted therapies, ultimately improving treatment strategies and patient outcomes.

Track 04: Tumor Microenvironment

Tumor Microenvironment investigates the tumor microenvironment (TME) and its critical role in cancer progression, therapy resistance, and metastasis. Topics include angiogenesis, hypoxia, immune system interactions, and metabolic reprogramming within the TME. Understanding how the TME influences cancer biology will help in developing therapeutic strategies targeting the microenvironment to improve treatment efficacy and overcome resistance.

Track 05: Innovations in Cancer Research

Innovations in Cancer Research highlights groundbreaking advancements in cancer research, including new approaches in cancer diagnosis, treatment, and drug discovery. Key topics include targeted therapies, immunotherapy, and CRISPR gene-editing technologies. The track also explores the role of artificial intelligence in enhancing cancer research and clinical decision-making, aiming to improve patient outcomes through innovative therapeutic strategies.

Track 06: Cancer Immunology and Immunotherapy

Cancer Immunology and Immunotherapy examines the complex relationship between cancer and the immune system, focusing on mechanisms of immune evasion and the latest immunotherapy advancements. Topics include checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and strategies to overcome resistance to immunotherapy. This track emphasizes improving the effectiveness of immune-based treatments to enhance cancer patient outcomes by boosting immune responses and addressing therapeutic challenges. The goal is to explore innovative ways to harness the immune system’s power to fight cancer more effectively.

Track 07: Cancer Stem Cells and Therapeutics

Cancer Stem Cells and Therapeutics investigates the role of cancer stem cells (CSCs) in tumor growth, metastasis, and resistance to conventional treatments. CSCs are responsible for recurrence and therapy resistance, making them critical targets for effective cancer therapies. This track focuses on innovative strategies to target CSCs, including novel drugs, immunotherapies, and gene-editing techniques. By exploring new approaches to eliminate CSCs, the aim is to prevent tumor recurrence and metastasis, leading to more effective and long-lasting treatments for cancer patients.

Track 08: Biomarkers and Liquid Biopsy

Biomarkers and Liquid Biopsy focuses on the use of biomarkers for cancer detection, prognosis, and monitoring. This track emphasizes liquid biopsy as a non-invasive method for early cancer detection, offering advantages over traditional tissue biopsies. Liquid biopsy analyzes circulating tumor cells, DNA, RNA, and exosomes in bodily fluids like blood, enabling personalized treatment strategies. By identifying genetic alterations and monitoring tumor dynamics, liquid biopsy aids in tailoring therapies and tracking treatment response, thus improving patient outcomes and reducing the need for invasive procedures.

Track 09: Cancer Pharmacology and Drug Development

Cancer Pharmacology and Drug Development examines the mechanisms of action and metabolism of anticancer drugs, focusing on new drug classes, small molecules, biologics, and antibody-drug conjugates. It highlights novel drug delivery systems and explores strategies to overcome resistance mechanisms and enhance drug efficacy. The track aims to provide insights into the development of new cancer therapies to improve patient outcomes.

Track 10: Cancer Stem Cells and Therapeutics

Cancer Stem Cells and Therapeutics examines the role of cancer stem cells (CSCs) in tumor growth, metastasis, and resistance to conventional therapies. This track focuses on current research into CSC-targeting treatments, exploring novel drugs and strategies designed to eliminate CSCs. By targeting these cells, which are responsible for tumor recurrence and metastasis, the track aims to develop more effective therapies, offering hope for improved treatment outcomes and long-term cancer remission.

Track 11: Biomarkers and Liquid Biopsy

Biomarkers and Liquid Biopsy focuses on the discovery and validation of biomarkers for cancer detection and monitoring treatment. This track emphasizes the role of liquid biopsy as a non-invasive tool for early cancer detection. By analyzing circulating tumor cells, DNA, RNA, and exosomes, liquid biopsy enables accurate prognosis and facilitates personalized treatment strategies. The track aims to enhance diagnostic accuracy and treatment effectiveness, offering a promising approach for continuous monitoring of cancer progression and response to therapy.

Track 12: Oncologic Imaging and Diagnostics

Oncologic Imaging and Diagnostics covers the latest advancements in oncologic imaging and diagnostic techniques, including PET-CT, MRI, molecular imaging, and radiomics. It explores how artificial intelligence and next-generation sequencing are enhancing tumor characterization and patient monitoring, providing insights into how these technologies can improve cancer diagnosis, treatment planning, and outcomes.

Track 13: Artificial Intelligence in Cancer Research

Artificial Intelligence in Cancer Research explores the transformative role of AI in cancer research and clinical applications. This track focuses on using AI for tumor classification, drug discovery, and predictive modeling to improve diagnosis and treatment outcomes. It also addresses the ethical considerations of integrating AI into healthcare systems, emphasizing the need for responsible use of technology in clinical settings. By harnessing AI, the track aims to enhance precision medicine and accelerate breakthroughs in cancer treatment.

Track 14: Cancer Epidemiology and Public Health

Cancer Epidemiology and Public Health explores global cancer trends, risk factors, and lifestyle influences. This track addresses the environmental and genetic factors contributing to cancer development and emphasizes cancer prevention through public health measures, including early detection programs, vaccination initiatives, and education on reducing cancer risk factors such as smoking, diet, and physical inactivity.

Track 15: Cancer Vaccines and Preventive Strategies

Cancer Vaccines and Preventive Strategies focuses on the development of therapeutic and preventive cancer vaccines, including promising new approaches like mRNA vaccines, dendritic cell-based vaccines, and oncolytic viruses. It also explores the role of vaccines in cancer prevention and the implementation of public health strategies to reduce cancer incidence through vaccination and other preventive measures.

Track 16: Radiation Therapy

Radiation Therapy focuses on advancements in radiotherapy techniques, including precision radiotherapy and proton therapy. This track explores the integration of AI in treatment planning to enhance precision and effectiveness. It also addresses strategies to minimize side effects while improving patient outcomes, aiming to optimize radiation therapy for better targeting of tumors and reducing damage to healthy tissue. The track seeks to highlight innovative approaches that improve the overall effectiveness and safety of radiation treatments for cancer patients.

Track 17: Cancer Control and Survivorship Care

Cancer Control and Survivorship Care focuses on the ongoing care of cancer survivors, addressing long-term physical and psychological challenges. This track explores rehabilitation, emotional support, and strategies to improve quality of life after treatment. It emphasizes the importance of managing survivorship issues such as fatigue, pain, mental health, and the risk of recurrence, with the goal of enhancing the overall well-being of cancer survivors and helping them navigate life after cancer treatment.

Track 18: Pediatric Oncology

Pediatric Oncology focuses on the unique challenges of diagnosing and treating cancer in children. This track explores the latest advancements in pediatric oncology, including targeted therapies and immunotherapy. It also examines the psychosocial impact of cancer on children and their families, as well as strategies to improve care and quality of life for young patients.

Track 19: Artificial Intelligence in Cancer Research

Artificial Intelligence in Cancer Research highlights the transformative role of artificial intelligence in cancer research and clinical applications. Topics include machine learning algorithms for tumor classification, drug discovery, predictive modeling, and the ethical considerations surrounding AI integration in cancer care. The track emphasizes how AI can enhance precision medicine and accelerate cancer research breakthroughs.

Benefits of Participation

Benefits for Speaker

Gain global recognition for your research profile worldwide.
Earn professional credits to support your career advancement.
Stay updated with the latest advancements in cutting-edge research.
Foster lasting connections through social and networking events.
Promote your research effectively through a one-page ad featured in abstract books and flyers, reaching a million views and significantly enhancing your research profile.
Expand your knowledge beyond your core field of Cancer Biology by exploring new subjects and areas of study.
Experience a unique blend of networking, learning, and enjoyable interactions, all in one comprehensive package.

Benefits for Delegate

Enhance your professional development by deepening your understanding and knowledge.
Your involvement contributes to the development of innovative methodologies and ideologies that can expand business and industry outcomes.
Connect with fellow Cancer Biology summit researchers and experts, fostering opportunities to exchange fresh ideas and insights within the field.

Benefit for Sponsor

Immerse yourself in an international environment to enhance the potential for new company opportunities.
Showcase your company's latest technologies, new products, or services to a diverse global audience.
Boost your business growth by generating leads through active participation.
Building a successful company requires considerable time, effort, and determination. It's invaluable to have a network of colleagues and associates who share a common drive and objective to draw inspiration from.
Evaluate and advance your organizational strategies by benchmarking against leading industry plans.
Gain valuable insights and solutions to your company's questions and challenges through feedback from trusted experts during our webinars.
Elevate your company's branding and marketing through prominent placement of your company's logo on our banners, website, and other event materials.

Benefit for Collaborators

This is the premier platform globally for showcasing Cancer Biology to an extensive audience.
Cultivate enduring professional relationships.
Elevate your subscriber/member base by 40% through strategic placement of your organization's branding, marketing materials, promotional content, and logo on our banners, website, and event materials.
Listing your company in the Global Business forum will significantly amplify its exposure through our event.
Your representatives can engage in valuable networking opportunities to enhance their knowledge and understanding of your organization's services and offerings alongside key delegates.
Cancer Biology advertising materials, including posters, brochures, pamphlets, and services, will be seamlessly integrated with information and distributed to hospitals, universities, societies, and researchers

Young Scientist Benefits

Our conferences provide best Platform for your research through oral presentations.
Share the ideas with both eminent researchers and mentors.
Young Scientist Award reorganization certificate and memento to the winners
Young Scientists will get appropriate and timely information by this Forum.
Platform for collaboration among young researchers for better development
Award should motivate participants to strive to realize their full potential which could in turn be beneficial to the field as whole.

Visa Trip Advisor

Planning a trip to Rome, Italy? Attend our Meeting!

Issue with VISA?

To support participants in their VISA application process, we provide VISA support documents as follows:

1. Official Letter of Invitation
2. Official Letter of Abstract Acceptance
3. Receipt of Payment

Points to note:

Visa Letter (official letter of invitation) will be issued only after successful registration and payment for the conference.
Visa Letters can be issued only for the individual accepted to attend the conference.
Please contact the Program Manager – Joe Howard, via [email protected] to arrange for a Visa Letter.

Kindly provide us with the following information for Visa Letters:

Your name as it appears on your passport
Passport Scan Copy (passport number and date of birth)
Abstract Acceptance letter

Payment Methods:

1. Payment Gateway - RAZORPAY
2. Bank-to-Bank transfer

Having trouble with registration?

Please contact Program Manager – Elena Hawkins via [email protected] The CANCER BIOLOGY- 2025 team will provide you with an INVOICE for the requested price, enabling you to make the Bank-to-Bank transfer.

Market Analysis

The global market for CANCER BIOLOGY- 2025 is expected to experience substantial growth, with projections indicating it will reach USD 365.25 billion by 2032, growing at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2032?. This growth is largely driven by the increasing incidences of cancer, significant research and development in cancer treatment, and the growing demand for personalized medicine?

In particular, immunotherapy is expected to be one of the fastest-growing segments in the oncology drugs market. This is attributed to advancements in drug development and the integration of new technologies like AI to enhance the effectiveness of cancer treatments?. For example, the FDA's approval of new drugs, like Ordered for breast cancer, and increasing R&D investments by companies, are propelling the demand for such therapies?.

Regionally, North America remains the largest market for oncology drugs, driven by high cancer prevalence and continuous product innovations?. However, the Asia Pacific region is forecast to show the highest growth due to rising cancer awareness and increasing healthcare expenditure?

?Key players in the industry include major pharmaceutical companies such as Roche, Merck, and Bristol-Myers Squibb, which continue to dominate the market with their strong portfolios and ongoing research. This landscape reflects an exciting time for innovation in cancer therapeutics, offering numerous opportunities for growth in the coming decade.